2023 World Conference on Lung Cancer (Posters)-EP12.01. Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases

EP12.01. Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases - PDF(Abstract)

Back to course

Pdf Summary

This case presentation discusses the successful salvage therapy of a patient with metastatic non-small cell lung cancer (NSCLC) using high dose Aumolertinib. The patient had T790M-negative EGFR mutation and developed brain and leptomeningeal metastases after resistance to previous first and third-generation TKI treatments. <br /><br />The patient, a 72-year-old Chinese woman, was diagnosed with stage IVB poorly differentiated adenocarcinoma. Initial treatment with icotinib plus bevacizumab resulted in a partial response. However, after 12 months, the patient experienced dizziness and headache, and imaging revealed progression of the disease with brain and leptomeningeal metastases. Further testing showed the loss of T790M mutation.<br /><br />The treatment was switched to double dose furmonertinib, but after 2 months, the patient had progressive disease. High dose Aumolertinib, known for its favorable efficacy against CNS metastases, was then initiated at 220mg daily. The patient achieved a partial response with a progression-free survival of over 9 months. Aumolertinib provided relief from leptomeningeal metastases symptoms and shrank brain lesions. No adverse events occurred during treatment.<br /><br />This case demonstrates the safety and efficacy of high dose Aumolertinib as a salvage therapy for T790M-negative EGFR-mutant NSCLC with brain and leptomeningeal metastases. It highlights the importance of considering alternative treatment options in patients who develop resistance to previous TKI treatments. The use of Aumolertinib offers a viable strategy for rescuing targeted therapy in this population.<br /><br />Overall, this case underscores the potential of high dose Aumolertinib in providing clinical benefit and improving outcomes in patients with metastatic NSCLC. Further follow-up is ongoing to assess long-term survival and treatment efficacy.

Asset Subtitle

Yi-Bin Li

Meta Tag

Speaker Yi-Bin Li

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

salvage therapy

metastatic non-small cell lung cancer

NSCLC

high dose Aumolertinib

T790M-negative EGFR mutation

brain metastases

leptomeningeal metastases

first and third-generation TKI treatments

furmonertinib

progression-free survival